Table 1.
MLH1 | PMS2 | MSH2 | MSH6 | Samples (%) | MSI status | sum |
---|---|---|---|---|---|---|
+ | + | + | + | 169 (78.6) | MSS | 169 |
- | + | + | + | 6 (2.8) | MSI | 46 |
+ | - | + | + | 22 (10.2) | ||
+ | + | - | + | 1 (0.5) | ||
+ | + | + | - | 7 (3.3) | ||
- | - | + | + | 10 (4.6) |
GC, gastric cancer; MSI, microsatellite instability; MSS, microsatellite stability. MLH1, PMS2, MSH2 and MSH6 immunohistochemical evaluations were completed in all 215 cases.